Claritas Pharmaceuticals, Inc. Stock

CLAZF

CA1806342061

Biotechnology & Medical Research

Delayed OTC Markets 21:16:04 27/02/2026 +04			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

Valuation: Claritas Pharmaceuticals, Inc.

Market Cap	5.37M 3.83M 3.34M 3.14M 2.86M 367M 5.38M 37.65M 14.51M 187M 14.38M 14.06M 603M	P/E 2019	-0.74x	P/E 2020	0.13x
Enterprise Value	6.29M 4.48M 3.91M 3.68M 3.35M 430M 6.3M 44.11M 17M 219M 16.85M 16.47M 706M	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	99.74%	Yield 2019 *	-	Yield 2020	-

* Estimated data More valuation ratios

Chart: Claritas Pharmaceuticals, Inc.

Dynamic Chart

Managers and Directors: Claritas Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Farrell CEO	Chief Executive Officer	76	21/06/2017
Victoria Rudman DFI	Director of Finance/CFO	58	29/06/2018

Director	Title	Age	Since
Robert Farrell CHM	Chairman	76	18/03/2021

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARITAS PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	37
LONZA GROUP AG	+0.59%	+2.73%	+1.48%	+28.74%	46.28B
IQVIA HOLDINGS INC.	+1.17%	+1.56%	+43.65%	+35.47%	43.85B
REVOLUTION MEDICINES, INC.	+0.86%	-6.33%	+332.63%	+530.35%	40.93B
BEONE MEDICINES AG	+4.21%	+3.20%	+8.10%	+94.46%	39.89B
CELLTRION, INC.	+1.11%	+1.80%	+11.52%	+43.15%	29.5B
MEDPACE HOLDINGS, INC.	+1.61%	+4.84%	+25.33%	+159.22%	17.09B
ASCENDIS PHARMA A/S	+0.61%	-10.16%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+2.12%	+8.18%	+24.54%	+41.21%	15.22B
TEMPUS AI, INC.	-0.28%	+26.02%	-8.71%	-	14.05B
Average	+1.24%	+3.57%	+54.82%	+133.23%	26.24B
Weighted average by Cap.	+1.50%	+2.08%	+68.65%	+141.69%

See all sector performances

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâ€™s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
CLAZF Stock

-40%: Exceptional extension

SEIZE THE OFFER!

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.4
10 years	0		15.31

Date	Insider	Type	Quantity	% Market Cap.
11/10/21	Andrew Salzman	Buy	118,000	0.3332%
11/10/21	Andrew Salzman	Buy	152,500	0.4307%
11/10/21	Andrew Salzman	Buy	24,500	0.0692%

	2019	2020
Net sales	-	-
Net income	-21.21M -15.13M -13.19M -12.42M -11.31M -1.45B -21.24M -149M -57.34M -738M -56.83M -55.57M -2.38B	4.21M 3M 2.62M 2.47M 2.25M 288M 4.22M 29.53M 11.38M 147M 11.28M 11.03M 473M
Net Debt	704K 502K 438K 412K 375K 48.1M 705K 4.94M 1.9M 24.5M 1.89M 1.84M 79.07M	920K 656K 572K 539K 491K 62.86M 921K 6.45M 2.49M 32.02M 2.46M 2.41M 103M

Claritas Pharmaceuticals, Inc. Stock

Stocks

CLAZF

CA1806342061

Biotechnology & Medical Research

Valuation: Claritas Pharmaceuticals, Inc.

Chart: Claritas Pharmaceuticals, Inc.

Price Extremes

Managers and Directors: Claritas Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile